Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid

Paddy K. C. Janssen; Norbert A. Foudraine; Desiree M. T. Burgers; Kees Neef; Jos L. M. L. le Noble

doi:10.1097/FTD.0000000000000330

Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid

Paddy K. C. Janssen, Norbert A. Foudraine, Desiree M. T. Burgers, Kees Neef, Jos L. M. L. le Noble^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Web of Science)

Original language	English
Pages (from-to)	699-705
Journal	Therapeutic Drug Monitoring
Volume	38
Issue number	6
DOIs	https://doi.org/10.1097/FTD.0000000000000330
Publication status	Published - Dec 2016

Keywords

cefuroxime
population pharmacokinetics
continuous venovenous hemofiltration
acute kidney injury

Access to Document

10.1097/FTD.0000000000000330

Cite this

Janssen, P. K. C., Foudraine, N. A., Burgers, D. M. T., Neef, K., & le Noble, J. L. M. L. (2016). Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid. Therapeutic Drug Monitoring, 38(6), 699-705. https://doi.org/10.1097/FTD.0000000000000330

Janssen, Paddy K. C. ; Foudraine, Norbert A. ; Burgers, Desiree M. T. ; Neef, Kees ; le Noble, Jos L. M. L. / Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid. In: Therapeutic Drug Monitoring. 2016 ; Vol. 38, No. 6. pp. 699-705.

@article{56eb3b51d6704050b9b1cd9ac63dd25a,

title = "Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid",

keywords = "cefuroxime, population pharmacokinetics, continuous venovenous hemofiltration, acute kidney injury",

author = "Janssen, {Paddy K. C.} and Foudraine, {Norbert A.} and Burgers, {Desiree M. T.} and Kees Neef and {le Noble}, {Jos L. M. L.}",

year = "2016",

month = dec,

doi = "10.1097/FTD.0000000000000330",

language = "English",

volume = "38",

pages = "699--705",

journal = "Therapeutic Drug Monitoring",

issn = "0163-4356",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "6",

}

Janssen, PKC, Foudraine, NA, Burgers, DMT, Neef, K & le Noble, JLML 2016, 'Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid', Therapeutic Drug Monitoring, vol. 38, no. 6, pp. 699-705. https://doi.org/10.1097/FTD.0000000000000330

Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid. / Janssen, Paddy K. C.; Foudraine, Norbert A.; Burgers, Desiree M. T.; Neef, Kees ; le Noble, Jos L. M. L.

In: Therapeutic Drug Monitoring, Vol. 38, No. 6, 12.2016, p. 699-705.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid

AU - Janssen, Paddy K. C.

AU - Foudraine, Norbert A.

AU - Burgers, Desiree M. T.

AU - Neef, Kees

AU - le Noble, Jos L. M. L.

PY - 2016/12

Y1 - 2016/12

KW - cefuroxime

KW - population pharmacokinetics

KW - continuous venovenous hemofiltration

KW - acute kidney injury

U2 - 10.1097/FTD.0000000000000330

DO - 10.1097/FTD.0000000000000330

M3 - Article

C2 - 27494946

VL - 38

SP - 699

EP - 705

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 6

ER -